| Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors |
141 |
| CXCL CXCL CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy |
121 |
| Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies |
51 |
| Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy |
48 |
| Drug resistance in multiple myeloma |
46 |
| Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma |
45 |
| Tumor-associated macrophages in breast cancer: Innocent bystander or important player? |
44 |
| PARP inhibitors in ovarian cancer |
40 |
| Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence |
38 |
| Targeting the microenvironment in solid tumors |
37 |
| Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases |
36 |
| Cancer stem cell in breast cancer therapeutic resistance |
33 |
| Molecular targeted therapy of glioblastoma |
31 |
| The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios |
30 |
| Management of metastatic bladder cancer |
29 |
| Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype |
29 |
| Hyperprogression as a distinct outcome after immunotherapy |
28 |
| Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies |
28 |
| The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review |
27 |
| Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? |
25 |
| PD-1 blockade in advanced NSCLC: A focus on pembrolizumab |
24 |
| Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond |
23 |
| Outlooks on Epstein-Barr virus associated gastric cancer |
23 |
| Treatment of advanced HER2-positive breast cancer: 2018 and beyond |
22 |
| Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out |
22 |
| Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis |
22 |
| Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation |
22 |
| Hedgehog signaling inhibitors in solid and hematological cancers |
22 |
| Triple negative breast cancer in Asia: An insider's view |
21 |
| Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma |
21 |
| Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition |
21 |
| RET fusions in solid tumors |
21 |
| Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives |
20 |
| Metabolomics in breast cancer: A decade in review |
20 |
| Novel urinary biomarkers for the detection of bladder cancer: A systematic review |
20 |
| Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium |
19 |
| Checkpoint inhibitors in breast cancer - Current status |
19 |
| Gastric cancer: Translating novels concepts into clinical practice |
19 |
| The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality |
19 |
| BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall |
18 |
| New therapeutic targets in pancreatic cancer |
18 |
| Staging and surgical approaches in gastric cancer: A systematic review |
18 |
| Checkpoint inhibitors in pancreatic cancer |
17 |
| New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology |
17 |
| Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer |
17 |
| eHealth for improving quality of life in breast cancer patients: A systematic review |
16 |
| Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies |
16 |
| Exercise training in childhood cancer: A systematic review and meta-analysis of randomized controlled trials |
16 |
| Immune checkpoint inhibitors for metastatic bladder cancer |
16 |
| PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis |
15 |
